Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

Recruiting now

Conditions studied: Hereditary Transthyretin-mediated (hATTR) Amyloidosis, Polyneuropathy

In brief

The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.

Key facts

Study ID

NCT05040373

Run by

Alnylam Pharmaceuticals

People needed

10

Starts

2020-08-01

Expected to finish

2030-10-12

Last updated by the study team

2026-06-01

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy

You may not qualify if…

• There are no exclusion criteria for participation in this program.

Where it is running

• Clinical Trial Site — Iowa City, Iowa, United States (enrolling)
• Clinical Trial Site — Nantes, France (enrolling)
• Clinical Trial Site — Münster, Germany (enrolling)
• Clinical Trial Site — Pavia, Italy (enrolling)
• Clinical Trial Site — Groningen, Netherlands (enrolling)
• Clinical Trial Site — Lisbon, Portugal (enrolling)
• Clinical Trial Site — Madrid, Spain (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.